Ocuphire Pharma, Inc.

OCUP

N/A

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

0.75% Phentolamine Ophthalmic Solution Phase 3 Results Expected

March 2026~0.75% phentolamine ophthalmic solution200

Primary completion for 0.75% Phentolamine Ophthalmic Solution trial (NCT07140783) in Vision Loss Night

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist

Phase 3

Mesopic Vision

Phentolamine Opthalmic Solution 0.75%

Phase 3

Presbyopia

0.75% phentolamine ophthalmic solution

Phase 3

Presbyopia

Phentolamine Ophthalmic Solution Vehicle

Phase 3

Mydriasis

Phentolamine Ophthalmic Solution 0.75%

Phase 3

Mydriasis

Phentolamine Mesylate Ophthalmic Solution 1%

Phase 2

Open Angle Glaucoma

Pilocarpine

Phase 2

Presbyopia

APX3330

Phase 2

Diabetic Retinopathy

Phentolamine Mesylate Ophthalmic Solution 1.0%

Phase 2

Night Vision Complaints

Drug Name	Phase	Indication	Designations
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist	Phase 3	Mesopic Vision	-
Phentolamine Opthalmic Solution 0.75%	Phase 3	Presbyopia	-
0.75% phentolamine ophthalmic solution	Phase 3	Presbyopia	-
Phentolamine Ophthalmic Solution Vehicle	Phase 3	Mydriasis	-
Phentolamine Ophthalmic Solution 0.75%	Phase 3	Mydriasis	-
Phentolamine Mesylate Ophthalmic Solution 1%	Phase 2	Open Angle Glaucoma	-
Pilocarpine	Phase 2	Presbyopia	-
APX3330	Phase 2	Diabetic Retinopathy	-
Phentolamine Mesylate Ophthalmic Solution 1.0%	Phase 2	Night Vision Complaints	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

OCUP News